These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7308093)

  • 1. Immunologic aspects of head and neck cancer.
    Dichtel WJ
    Ear Nose Throat J; 1981 Oct; 60(10):97-100, 102,-6. PubMed ID: 7308093
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours.
    Quak J; Gerretsen M; De Bree R; Brakenhof R; Van Dongen G; Snow G
    Anticancer Res; 1993; 13(6B):2533-9. PubMed ID: 8135493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer.
    Andratschke M; Pauli C; Stein M; Chaubal S; Wollenberg B
    Anticancer Res; 2003; 23(2B):1467-71. PubMed ID: 12820411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Our immunological investigations in the cancer of the head and neck (author's transl)].
    Krajina Z; Kosoković F; Kosovski V; Poljak Z
    Lijec Vjesn; 1976 Jan; 98(1):32-4. PubMed ID: 940413
    [No Abstract]   [Full Text] [Related]  

  • 5. Head and neck cancer antigens recognized by the humoral immune system.
    Monji M; Senju S; Nakatsura T; Yamada K; Sawatsubashi M; Inokuchi A; Nishimura Y
    Biochem Biophys Res Commun; 2002 Jun; 294(3):734-41. PubMed ID: 12056832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer.
    van Dongen GA; Brakenhoff RM; ten Brink CT; van Gog FB; de Bree R; Quak JJ; Snow GB
    Anticancer Res; 1996; 16(4C):2409-13. PubMed ID: 8816843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of immunology and head and neck tumors.
    Church JM; Ryan RF
    Clin Plast Surg; 1976 Jul; 3(3):385-8. PubMed ID: 963948
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological methods in diagnosis and monitoring of head and neck cancer.
    Mitchell MS
    Laryngoscope; 1978 Jan; 88(1 Pt 2 Suppl 8):18-9. PubMed ID: 339021
    [No Abstract]   [Full Text] [Related]  

  • 9. Allogenic antibody-mediated identification of head and neck cancer antigens.
    Rauch J; Ahlemann M; Schaffrik M; Mack B; Ertongur S; Andratschke M; Zeidler R; Lang S; Gires O
    Biochem Biophys Res Commun; 2004 Oct; 323(1):156-62. PubMed ID: 15351715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.
    Kienstra MA; Neel HB; Strome SE; Roche P
    Head Neck; 2003 Jun; 25(6):457-63. PubMed ID: 12784237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunocompetence and immunotherapy in patients with cancer of the head and neck region].
    Vinzenz K; Micksche M
    Z Stomatol; 1986 May; 83(3):203-18. PubMed ID: 3465128
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy in head and neck cancer: current practice and future possibilities.
    Agada FO; Alhamarneh O; Stafford ND; Greenman J
    J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
    Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
    Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus and head and neck cancer: a growing concern.
    Gillespie MB; Smith J; Gibbs K; McRackan T; Rubinchik S; Day TA; Sutkowski N
    J S C Med Assoc; 2008 Dec; 104(8):247-51. PubMed ID: 19326612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunology of cancer of the head and neck with particular reference to oral cancer.
    Scully C
    Oral Surg Oral Med Oral Pathol; 1982 Feb; 53(2):157-69. PubMed ID: 6276835
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody responses to survivin and their clinical significance in patients with head and neck cancer.
    Eto M; Kodama S; Uemura N; Suzuki M
    Head Neck; 2007 Dec; 29(12):1128-35. PubMed ID: 17636541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
    Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
    Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of poor CD3 response in head and neck cancer.
    Shibuya TY; Nugyen N; McLaren CE; Li KT; Wei WZ; Kim S; Yoo GH; Rogowski A; Ensley J; Sakr W
    Clin Cancer Res; 2002 Mar; 8(3):745-51. PubMed ID: 11895904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of head and neck cancer.
    Castro JE
    Clin Otolaryngol Allied Sci; 1977 Feb; 2(1):65-75. PubMed ID: 338211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.